SeQureDX
formerly SeQure DxAcquiredSLOT GACOR ✈️ SELAMAT DATANG DI BANDAR SLOT GACOR ASIA RESMI
United States · Founded 2021
- Employees
- 51–200
- Founded
- 2021
- Business Model
- B2B
- Acquisition Date
- Jan 2025
About
SeQure Dx provides on-target and off-target gene editing assessment services for cell and gene therapy developers. Its assay portfolio, including ONE-seq and GUIDE-seq platforms, helps developers confirm editing precision, reduce safety risk, and support regulatory submissions from early discovery through IND. Co-founded by Dr. J. Keith Joung, the company emerged with evaluation assays for off-target risk validation and candidate optimization. MaxCyte acquired SeQure Dx in January 2025, and the SeQure assays now operate as MaxCyte's dedicated gene-editing risk assessment platform.
Summary
SeQureDX is a Biotech company based in United States, founded in 2021.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2025
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/sequredx"><img src="https://indexed.vc/api/badge/company/sequredx" alt="SeQureDX on Indexed.vc" width="260" height="76" /></a>